Search

Your search keyword '"Clifton-Bligh RJ"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Clifton-Bligh RJ" Remove constraint Author: "Clifton-Bligh RJ"
155 results on '"Clifton-Bligh RJ"'

Search Results

1. Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study.

2. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

3. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) parathyroid tumors demonstrate distinctive morphologic features

4. TERT structural rearrangements in metastatic pheochromocytomas

5. Bayesian approach to determining penetrance of pathogenic SDH variants

6. Clinical guidance for radioiodine refractory differentiated thyroid cancer

7. Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types

8. Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas

11. Preventing OsteoPorosis in Spinal Cord Injury (POPSCI) Study-Early Zoledronic Acid Infusion in Patients with Acute Spinal Cord Injury.

12. Author response to: OSIN-D-24-00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

13. SDHA-related phaeochromocytoma and paraganglioma: review and clinical management.

14. Extending the Therapeutic Potential: Romosozumab in Osteoporosis Management.

15. Gene-based association analysis of a large patient cohort provides insights into genetics of atypical femur fractures.

16. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

17. Study protocol for the ROLEX-DUO randomised placebo-controlled trial: ROmosozumab Loaded with EXercise - DUal effects on bone and muscle in postmenopausal Osteoporosis and Osteopenia.

18. Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol.

19. Outcomes of SDHB Pathogenic Variant Carriers.

20. Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma.

21. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

22. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer.

23. A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma.

24. Medullary Thyroid Cancer: Updates and Challenges.

25. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.

26. Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.

27. Asia-Pacific Consensus Recommendations on X-Linked Hypophosphatemia: Diagnosis, Multidisciplinary Management, and Transition From Pediatric to Adult Care.

28. Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring.

29. The length of FOXE1 polyalanine tract in congenital hypothyroidism: Evidence for a pathogenic role from familial, molecular and cohort studies.

30. Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update.

31. Homozygous Ser-1 to Pro-1 mutation in parathyroid hormone identified in hypocalcemic patients results in secretion of a biologically inactive pro-hormone.

32. The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy.

33. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Pheochromocytoma and Paraganglioma.

34. Foxe1 Deletion in the Adult Mouse Is Associated With Increased Thyroidal Mast Cells and Hypothyroidism.

35. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.

36. Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.

37. International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma.

38. Novel TSHB variant (c.217A>C) causing severe central hypothyroidism and pituitary hyperplasia.

39. Immune Related Adverse Events of the Thyroid - A Narrative Review.

40. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.

41. Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study.

42. Risk stratification of indeterminate thyroid nodules using ultrasound and machine learning algorithms.

43. Asian Ethnicity and Femoral Geometry in Atypical Femur Fractures: Independent or Interdependent Risk Factors?

44. A contemporary clinical approach to genetic testing for heritable hyperparathyroidism syndromes.

45. Papillary thyroid microcarcinoma: Is active surveillance always enough?

46. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.

47. Translational Utility of Liquid Biopsies in Thyroid Cancer Management.

48. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers.

49. The Sydney AFF Score: A Simple Tool to Distinguish Females Presenting With Atypical Femur Fractures Versus Typical Femur Fractures.

50. Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer.

Catalog

Books, media, physical & digital resources